Rani Therapeutics
RANI
34 hedge funds and large institutions have $17.6M invested in Rani Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 32 → 34 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.04% less ownership
Funds ownership: 12.96% → 11.93% (-1%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
42% less capital invested
Capital invested by funds: $30.4M → $17.6M (-$12.8M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$280K |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$247K |
| 3 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
+$244K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$132K |
| 5 |
E
Ergoteles
New York
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
-$1.49M |
| 2 |
BlackRock
New York
|
-$1.02M |
| 3 |
ISB
Iowa State Bank
Urbandale,
Iowa
|
-$181K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$179K |
| 5 |
Millennium Management
New York
|
-$117K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AF
26
Allworth Financial
Folsom,
California
| $18.4K | +$22.8K | +3,119 | New |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $15K | +$8.23K | +1,129 | +82% |
|
28
Morgan Stanley
New York
| $12.8K | -$18.6K | -2,544 | -54% |
|
29
UBS Group
Zurich,
Switzerland
| $5.9K | – | – | – |
|
30
JP Morgan Chase
New York
| $5K | -$4.43K | -608 | -44% |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$15 | -2 | -2% |
|
32
Simplex Trading
Chicago,
Illinois
| $1K | +$569 | +78 | +35% |
|
|
FCA
33
FinTrust Capital Advisors
Greenville,
South Carolina
| $442 | +$547 | +75 | New |
|
34
Wells Fargo
San Francisco,
California
| $413 | +$15 | +2 | +3% |
|
|
ISB
35
Iowa State Bank
Urbandale,
Iowa
| – | -$181K | -18,862 | Closed |
|
|
36
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$179K | -18,712 | Closed |
|
37
Citigroup
New York
| – | -$3K | -295 | Closed |
|
|
CUAMC
38
China Universal Asset Management Company
Shanghai,
China
| – | -$2K | -229 | Closed |
|
39
BNP Paribas Financial Markets
Paris,
France
| – | -$1.45K | -151 | Closed |
|
40
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -58 | Closed |
|
RANI Hedge Fund Activity: Q4 2022 in Review
34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q4 2022, worth a combined $17.6M — down 42% from $30.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RANI positions and 6 closed out — a net gain of 2 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $280K. The largest seller was Alphabet Inc, cutting an estimated $1.49M.
- 34 institutional investors held Rani Therapeutics (RANI) as of Q4 2022, up from 32 in Q3 2022.
- Funds reported $17.6M of Rani Therapeutics stock for Q4 2022, down 42% quarter-over-quarter.
- 8 funds opened new Rani Therapeutics positions in Q4 2022 and 6 closed out, a net change of +2 holders.
- The largest Rani Therapeutics buyer in Q4 2022 was Renaissance Technologies, an estimated $280K added.
- The largest Rani Therapeutics seller in Q4 2022 was Alphabet Inc, an estimated $1.49M sold.
Based on aggregated 13F filings for Q4 2022.